Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | SHBG | P04278 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | ANPEP | P15144 | 2/20 | 0.36 |
| ▸ | ERAP2 | Q6P179 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675445 | 0.98 | EPHX1 (0.36) | EPHX1SHBGDPP4TP53ANPEP | |
| SCHEMBL13675449 | 0.93 | — | — | |
| SCHEMBL13675439 | 0.88 | — | — | |
| SCHEMBL28291254 | 0.80 | SIGMAR1 (0.39) | EPHX1SHBGDPP4TP53KDM4E | |
| SCHEMBL13675428 | 0.80 | CARM1 (0.32) | ANPEP | |
| SCHEMBL13673867 | 0.80 | EPHX1 (0.38) | EPHX1SHBGDPP4TP53ANPEP | |
| SCHEMBL13673902 | 0.77 | EPHX1 (0.34) | EPHX1SHBGDPP4TP53ANPEP | |
| SCHEMBL18849339 | 0.77 | KDM4E (0.56) | EPHX1DPP4TP53ANPEPERAP2 | |
| SCHEMBL12023103 | 0.75 | TP53 (0.41) | EPHX1SHBGTP53ANPEPERAP2 | |
| SCHEMBL24331662 | 0.74 | SHBG (0.41) | EPHX1SHBGTP53KDM4EGMNN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3154937-B1 | CHLORINE-RESISTANT POLYETHYLENE COMPOUND AND ARTICLES MADE THEREFROM | FINA TECHNOLOGY (US) | 2024-05-22 | — | — | EP | claimed |
| EP-2139472-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2010-01-06 | — | — | EP | disclosed |
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| WO-2008116926-A1 | TETRAHYDROINDOLE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYO TEX SA (CH) | 2008-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247519-A1 | AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE | PKD2, PKD1, AADAT | EPHX1 1379/4885SHBG 4484/4885DPP4 1106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.